Richard

Connors

[email protected]

Dr. Connors has extensive training and experience in drug discovery. His first industrial job was at Pharmacopeia, a company in Princeton, NJ specializing in combinatorial chemistry. Four years later, he relocated to the Bay Area, taking up a position at Tularik, a biotech focused on nuclear receptor targets. Tularik was acquired by Amgen in 2004 and Dr. Connors remained with Amgen until they shut down Medicinal Chemistry in South San Francisco in late 2014. While at Amgen, Dr. Connors participated in three projects advancing molecules to clinical trials.